Warren Buffett Detailed Fundamental Analysis

Validea's guru fundamental report indicates Zoetis Inc. (ZTS), a large-cap growth stock in the Biotechnology & Drugs sector, rates 82% using its 'Patient Investor' model, which aligns with Warren Buffett's strategy. This model targets firms with predictable profitability, low debt, and reasonable valuations. The 82% score signifies notable interest, with ZTS passing most key fundamental criteria, positioning it as a potential consideration for long-term, value-oriented portfolios.

Analysis

Zoetis Inc. (ZTS) scores a favorable 82% on Validea's 'Patient Investor' fundamental model, which is based on Warren Buffett's investment strategy. This score indicates a notable level of interest, as it surpasses the 80% threshold for consideration. The analysis highlights ZTS's alignment with key Buffett-style criteria, specifically passing tests for earnings predictability, manageable debt service, high return on equity, and strong free cash flow generation. Furthermore, the company is recognized for its effective use of retained earnings and shareholder-friendly share repurchases. The model also deems the stock's valuation to be reasonable, as evidenced by passing grades on both initial and expected rates of return. The sole point of failure identified in the screen is on the 'Return on Total Capital' metric, suggesting a potential area of inefficiency in how the company deploys its combined debt and equity capital base, which warrants closer inspection despite the otherwise strong fundamental profile.

Key Decisions for Investors

• Investors with a long-term, value-oriented strategy should view the 82% rating as a strong positive signal, given the company's predictable earnings, shareholder-friendly capital allocation, and reasonable valuation according to the model.
• It is critical to conduct further due diligence on why Zoetis failed the 'Return on Total Capital' criterion, as this may indicate a less efficient use of its overall asset and debt structure compared to its peers.
• Given the passing marks on expected return and share repurchases, investors may consider the current valuation an attractive entry point for a fundamentally sound company, but should monitor capital efficiency metrics in future reports.